In this section you will find links to a wide range of information relating to organisations, accessing current clinical trials, ILD guidelines, research articles and many others online resources relating to Interstitial Lung Disease (ILD).
We endeavour to ensure the accuracy of the information provided, however, if you do have concerns with any information on this site I would be grateful if you could let me know by using the Contact form and I can investigate further and update or amend if necessary. Otherwise, I hope you will find the information below useful. Thank you.
Table of contents:
- Organisations and groups
- Clinical trials – Currently recruiting
- Travel insurance
- IPF FAQs
- ILD Guideline documents
- Telomerase research articles
- Breathing methods and techniques
- NHS Fitness Studio
- Improving Air Quality Initiatives
Pulmonary Fibrosis Foundation Summit November 2017
- Treating pulmonary fibrosis with co-trimoxazole
- AdAlta’s Shark Antibody, Potential Way of Treating Lung Fibrosis, Nearing 1st Clinical Trial
[http://erj.ersjournals.com/content/48/suppl_60/PA2425 – In patients with systemic sclerosis a ratio between Forced-Vital-Capacity (FVC) and diffusing capacity of carbon-monoxide (DLCO, FCV%/DLCO%) >1.5 could be a predictor of pulmonary hypertension (PH). The aim of this study was therefore to evaluate whether this index could be used in patients with PH, regardless of etiology.]
It is unclear how or if the ratio of FVC/DLCO can also be used as a reliable indicator for early diagnostics for Pulmonary Hypertension (PH) or for early indication of increased Pulmonary Arterial Pressure (PAP) in IPF patients.
So what does IPF sound like when recorded using a high quality stethoscope?
- IPF Care Patient Support Program
- Pulmonary Wellness Guide
- Syndromes of Telomere Shortening
- Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
- Lung transplantation in telomerase mutation carriers with pulmonary fibrosis
- Adult-onset pulmonary fibrosis caused by mutations in telomerase
- The Efficacy of Pirfenidone in the Treatment of IPF: A Single-Institution Retrospective Study in Japan
- POINT: Should All Patients With IPF, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes
- Pulmonary Fibrosis Flare-up Changes Patients’ Respiratory Bacteria Mix, Study Reports
- Promising emerging therapies for the treatment of IPF – 13 Nov 2015
Guided relaxation to help with your breathing:
The following recording is a guided relaxing exercise to help control your breathing. Before playing the recording be in a relaxed and comfortable place and make sure that you will not be interrupted during the session.